CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

Regeneron acquires bankrupt 23andMe for $256M. What this DNA data sale means for privacy, pharma, and your genetic information.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge greenlighted the sale of the remnants of the firm, including its wealth of ...

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

This editorial originally ran in fellow CNHI paper The (Sunbury). Individuals have long valued privacy for themselves and their families, while often — knowingly or unknowingly — giving it away. It is ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder ...

Anne Wojcicki's nonprofit TTAM Research Institute will purchase "substantially all" of San Francisco-based 23andMe's assets.

With several high-profile drugmakers already lining up for manufacturing space, Fujifilm Biotechnologies is on the cusp of ...

The clock is ticking and you've got less than 2 weeks left to file a claim and get part of the 23andMe class-action settlement.

A court has approved the $305m sale of 23andMe’s assets to a nonprofit led by former 23andMe CEO Anne Wojcicki.

Genetic testing company 23andMe can proceed with a US$305-million sale to the company’s co-founder Anne Wojcicki after a U.S.